Advertisement

InflammoPharmacology

, Volume 9, Issue 1–2, pp 71–80 | Cite as

Review of gastrointestinal tolerability and safety of Meloxicam

  • Frank Degner
  • Bill Richardson
Article

Abstract

Selective COX-2 inhibition relative to COX-1 has consistently been demonstrated for meloxicam in various in vitro test systems. In human platelets ex vivo COX-1-dependent thromboxane formation is partially and dose dependently inhibited, however no significant inhibition of platelet aggregation has been observed with the recommended doses of 7.5 mg and 15 mg meloxicam daily. With once daily dosing, meloxicam has demonstrated efficacy in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Meloxicam was granted its first marketing authorization in 1995 and is now available in more than 100 countries. Meloxicam has been studied in clinical trials involving more than 30 000 patients and is estimated to have been prescribed for more than 30 million patients worldwide to date. Clinically, meloxicam offers similar efficacy to recommended doses of well-established nonsteroid anti-inflammatory drugs (NSAIDs), including diclofenac, piroxicam and naproxen. Meloxicam distinguishes itself from established NSAIDs with a reduced risk of certain gastrointestinal adverse events. This has consistently been demonstrated in randomized clinical trials, large scale clinical outcome studies, pooled analyses and meta-analyses. Post-marketing experience is consistent with the safety profile established in these studies and analyses.

MELOXICAM SELECTIVE COX-2 INHIBITION GASTROINTESTINAL TOLERABILITY OSTEOARTHRITIS RHEUMATOID ARTHRITIS ANKYLOSING SPONDYLITIS 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. Carrabba, M., Paresce, E., Angelini, M., et al (1995). A comparison of the local tolerability, safety and efficacy of meloxicam and piroxicam suppositories in patients with osteoarthritis: a single-blind, randomized, multicentre study, Curr. Med. Res. Opin. 13 (6), 343–355.Google Scholar
  2. Churchill, L., Graham, A. G., Shih, C. K., et al. (1996). Selective inhibition of human cyclo-oxygenase-2 by meloxicam, Inflammopharmacology 4, 125–135.Google Scholar
  3. Degner, F., Sigmund, R. and Zeidler, H. (2000). Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease, Clin. Ther. 22 (4), 400–410.Google Scholar
  4. De Meijer, A., Vollaard, H., de Metz, M., et al (1999). Meloxicam 15 mg/day spares platelet function in healthy volunteers, Clin. Pharmacol. Ther. 66, 425–430.Google Scholar
  5. Dequeker, J., Hawkey, C., Kahan, A., et al (1998). Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis, Brit. J. Rheumatol. 37 (9), 946–951.Google Scholar
  6. Distel, M., Mueller, C. and Bluhmki, E. (1996). Global analysis of gastrointestinal safety of a new NSAID, meloxicam, Inflammopharmacology 4, 71–81.Google Scholar
  7. Dougados, M., Gueguen, A., Nakache, J. P., et al (1999). Ankylosing spondylitis: what is the optimumduration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial, Rheumatology 38 (3), 235–244.Google Scholar
  8. Engelhardt, G., Homma, D., Schlegel, K., et al (1995). Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-in' ammatory agent with favourable gastrointestinal tolerance, Inflamm. Res. 44, 423–433.Google Scholar
  9. Furst, D., Hall, D., Roszko, P. J., et al (2000). Efficacy, Safety and Dose Response of Meloxicam up to 22.5 mg in the treatment of rheumatoid arthritis (RA): Results of a phase III double-blind, placebo controlled trial. ACR 64 th Annual Scientific Meeting, Philadelphia.Google Scholar
  10. Ghozlan, P. R., Bernhardt, M., Velicitat, P., et al (1996). Tolerability of multiple administration of intramuscular meloxicam: a comparison with intramuscular piroxicamin patients with rheumatoid arthritis or osteoarthritis, Brit. J. Rheumatol. 35 (Suppl. 1), 51–55.Google Scholar
  11. Goei The, H. S., Lund, B., Distel, M. R., et al (1997). A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee, Osteoarthritis Cartilage 5 (4), 283–288.Google Scholar
  12. Hawkey, C. J. (1999). COX-2 inhibitors, Lancet 353, 307–314.Google Scholar
  13. Hawkey, C., Kahan, A., Steinbrück, K., et al. (1998). Gastrointestinal tolerability of meloxicam com-pared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment, Brit. J. Rheumatol. 37 (9), 937–945.Google Scholar
  14. Hosie, J., Distel, M. and Bluhmki, E. (1996). Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium, Brit. J. Rheumatol. 35 (Suppl. 1), 39–43.Google Scholar
  15. Hosie, J., Distel, M. and Bluhmki, E. (1997). Efficacy and tolerabilityof meloxicamversus piroxicam in patients with osteoarthritisof the hip or knee: a six-month double-blindstudy, Clin. Drug Invest. 13 (4), 175–184.Google Scholar
  16. Huskisson, E. C., Narjes, H. and Bluhmki, E. (1994). Efficacy and tolerance of meloxicam, a new NSAID, in daily oral doses of 15, 30 and 60 mg in comparison to 20 mg piroxicamin patients with rheumatoid arthritis, Scand. J. Rheumatol. S98, 115.Google Scholar
  17. Lanes, S. F., Garcia Rodriguez, L. A. and Hwang, E. (2000). Baseline risk of gastrointestinal disorders among new users of meloxicam, ibuprofen, diclofenac, naproxen and indomethacin, Pharmacoepidemiol. Drug Safety 9, 113–117.Google Scholar
  18. Lemmel, E. M., Bolten, W., Burgos-Vargas, R., et al. (1997). Efficacy and safety of meloxicam in patients with rheumatoid arthritis, J. Rheumatol. 24, 282–290.Google Scholar
  19. Linden, B., Distel, M. and Bluhmki, E. (1996). A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip, Brit. J. Rheumatol. 35 (Suppl. 1), 35–38.Google Scholar
  20. Lund, B., Distel, M. and Bluhmki, E. (1998). A double-blind, randomized, placebo-controlledstudy of efficacy and tolerance of meloxicamtreatment in patients with osteoarthritis of the knee, Scand. J. Rheumatol. 27, 32–37.Google Scholar
  21. Martin, R. M., Biswas, P. and Mann, R. D. (2000). The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicamuse amongst 19087 patients in general practice in England: cohort study, Brit. J. Clin. Pharmacol. 50, 35–42.Google Scholar
  22. Panara, M. R., Renda, G., Sciulli, M. G., et al (1999). Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects, J. Phar-macol. Exp. Ther. 290 (1), 276–280.Google Scholar
  23. Patrignani, P., Panara, M. R., Sciulli, M. G., et al. (1997). Differential inhibition of human prostaglandinendoperoxide synthase-1 and-2 by nonsteroidal anti-inflammatory drugs, J. Physiol. Pharmacol. 48, 623–631.Google Scholar
  24. Schoenfeld, P. (1999). Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials, Amer. J. Med. 107 (Suppl. 6A), 48S–54S.Google Scholar
  25. Silverstein, F. E., Faich, G. F., Goldstein, J. L., et al (2000). Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis, J. Amer. Med. Assn. 284, 1247–1255.Google Scholar
  26. Stichtenoth, D. O., Wagner, B. and Frölich, J. C. (1997). Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers, J. Invest. Med. 45, 44–49.Google Scholar
  27. Van Hecken, A., Schwartz, J. I., Depre, M., et al. (2000). Comparative inhibitory activity of rofecoxib (MK-0966), meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 vs. COX-1 in healthy volunteers, J. Clin. Pharmacol. 40, 1109–1120.Google Scholar
  28. Warner, T., Giuliano, F., Vojnovic, I., et al. (1999). Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2are associated with human gastrointestinaltoxicity: A full in vitro analysis, Proc. Natl. Acad. Sci. USA 96, 7563–7568.Google Scholar
  29. Wojtulewski, J. A., Schattenkirchner, M., Barcelo, P., et al. (1996). A six-month double-blind trial to compare the efficacy and safety of meloxicam7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis, Brit. J. Rheumatol. 35 (Suppl. 1), 22–28.Google Scholar
  30. Yocum, D., Fleischmann, R., Dalgin, P., et al. (2000). Efficacy and safety of meloxicam in the treatment of osteoarthritis, Arch. Intern. Med. 160, 2947–2954.Google Scholar

Copyright information

© VSP 2001 2001

Authors and Affiliations

  • Frank Degner
    • 1
  • Bill Richardson
    • 1
  1. 1.Boehringer Ingelheim GmbH

Personalised recommendations